Dr. Jihad Mohamad Alhariri, MD

Dr. Alhariri practices at Johns Hopkins Dermatoimmunology Lab in Baltimore, Maryland.

Dr. Alhariri's NPI, 1659529253, was assigned on September 8, 2008. Dr. Alhariri holds Maryland license D0057987.

Dr. Alhariri's primary practice is Johns Hopkins Dermatoimmunology Lab, at 600 N Wolfe St Blalock Rm 907, Baltimore, MD 21287. The practice phone is (410) 955-3484.

Dr. Alhariri's primary practice is Johns Hopkins Dermatoimmunology Lab in Baltimore, Maryland. Dr. Alhariri is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Alhariri to 1 more hospital, named with a free account. Dr. Alhariri's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alhariri practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Alhariri's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Alhariri is licensed in Maryland.

CMS data shows 1,794 Medicare services from Dr. Alhariri across 15 procedure codes in 2024, for 669 Medicare patients. Medicare paid $70,918 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 669 Medicare patients who saw Dr. Alhariri in 2024. The largest group is 65 to 74, with 296 patients. 73% of them have high cholesterol, and 72% have high blood pressure. 25% are also on Medicaid. Their average risk score is 1.44, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Alhariri's median patient age at 70, with 53% women.

In 2024, Dr. Alhariri wrote 283 Medicare Part D claims for 102 patients. 78% of them were for generic drugs. CMS names the drug for 103 of them, across 5 drugs with 11 or more claims each, at $75,962 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Alhariri for performance year 2024, reported as part of a group. CMS counts 312 procedures of skin biopsy by Dr. Alhariri, more than 91% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 24 general payments to Dr. Alhariri from 11 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $549.